Clinical Trials

    Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) (TroFuse-005)

    Investigator: Pedro Ramirez

    Study Coordinator: Jaya Kamath

    Status: Enrolling

    ClinicalTrials.gov Number: NCT06132958

    Phone: 713.441.6616

    Protocol Number: PRO00037933

    Description


    Researchers are looking for new ways to treat people with endometrial cancer (EC) who have previously received treatment with platinum based therapy (a type of chemotherapy) and immunotherapy. Immunotherapy is a treatment that helps the immune system fight cancer. This clinical study will compare MK-2870 sacituzumab tirumotecan to chemotherapy. The goal of the study is to learn if people who receive MK-2870 sacituzumab tirumotecan live longer overall and without the cancer getting worse compared to people who receive chemotherapy.